Browse the evidence

In patients with Type 2 Diabetes, GLP-1RA use is strongly associated with prior use of insulin and multiple oral antidiabetic agents, indicating their role as intensification therapies for poorly controlled diabetes.

If you have Type 2 Diabetes and are already taking insulin or multiple oral medications, your provider is likely to prescribe a GLP-1RA as an intensification therapy. This is a standard and effective approach for managing blood sugar when other treatments are insufficient.

Mandibular advancement devices (MADs) provide symptom relief comparable to CPAP in mild-to-moderate OSA primarily due to superior long-term adherence, despite CPAP's superior objective efficacy in reducing AHI.

If you have mild-to-moderate sleep apnea and struggle with CPAP, ask about a mandibular advancement device. It might not reduce your apnea events as much as CPAP, but you are more likely to use it every night, which often leads to better overall health outcomes and symptom relief.

GLP-1-based therapies, particularly dual GLP-1/GIP agonists like tirzepatide, produce large, clinically meaningful reductions in AHI and cardiometabolic risk in obesity-associated OSA.

If you have obesity-related sleep apnea, ask your doctor about GLP-1/GIP agonists like tirzepatide. These medications can significantly reduce your apnea severity by reducing weight and metabolic load, offering a systemic treatment option.

Hypoglossal nerve stimulation (HNS) produces substantial, durable improvements in AHI and symptoms with high adherence, supported by randomized trials and real-world data.

If you have moderate-to-severe sleep apnea and cannot tolerate CPAP, ask about hypoglossal nerve stimulation (HNS). It is an implanted device that stimulates the tongue to keep the airway open, offering substantial and durable relief for the right candidate.

GLP-1 and GIP/GLP-1 agonists reduce systemic inflammation (hsCRP, IL-6) and improve metabolic parameters (HbA1c, blood pressure, lipids) in obese patients, contributing to overall cardiovascular risk reduction.

If you are obese, ask your doctor about GLP-1 agonists. They can significantly improve your blood pressure, blood sugar, and inflammation levels, reducing your overall risk of heart disease and stroke.

GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.

If you are struggling to lose weight on GLP-1 medications like liraglutide despite strict adherence, ask your doctor about pharmacogenetic testing for GLP1R variants. Your genetic makeup may dictate whether this specific drug is the right fit for you, helping you avoid ineffective treatments and switch to alternatives sooner.

Tirzepatide's dual GIP/GLP-1 receptor agonism provides a synergistic mechanism that enhances weight loss and mitigates gastrointestinal side effects compared to selective GLP-1 agonists.

Tirzepatide works differently than semaglutide by activating both GIP and GLP-1 receptors. This dual action may lead to greater fat loss and potentially fewer stomach side effects.

GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).

Tirzepatide is the first FDA-approved medical therapy for OSA, showing significant improvements in sleep apnea severity (AHI) in patients with obesity. This benefit occurs both in patients using CPAP and those not using it. It offers a new treatment option for those struggling with OSA, potentially reducing the burden of the disease.

Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.

Newer 'triple-agonist' weight loss medications target three different hormonal pathways (GLP-1, GIP, and Glucagon) instead of just one. Clinical trials show these can lead to over 20% body weight loss, which is significantly higher than older single-target drugs. These are currently experimental and not yet widely available for general use.

Lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin are associated with a reduced risk of acute kidney injury compared to control treatments.

If you are taking lixisenatide, high-dose canagliflozin, empagliflozin, or dapagliflozin, you may have a lower risk of acute kidney injury compared to those not on these medications. Continue to follow your doctor's recommendations for kidney function monitoring, as these benefits do not eliminate the need for standard care.

Tirzepatide (10 mg and 15 mg) significantly improves health-related quality of life (HR-QoL) in Japanese adults with obesity disease compared to placebo over 72 weeks.

For Japanese adults with obesity disease, treatment with tirzepatide (10 mg or 15 mg weekly, escalated from 2.5 mg) alongside lifestyle changes significantly improves quality of life, particularly physical function and psychosocial well-being, compared to placebo over 72 weeks.

Denosumab is the most promising pharmacological treatment for osteosarcopenia because it inhibits RANKL in both muscle and bone, leading to increased lean mass, bone mass, grip strength, and reduced fall risk.

Denosumab is currently the most promising drug for treating osteosarcopenia, showing benefits for both muscle and bone. However, it is still under further clinical investigation. It should be considered alongside, not instead of, resistance training and proper nutrition.

Protein or amino acid supplementation combined with resistance exercise training in older adults produces a positive but minor effect on whole-body lean mass growth, while having minimal and inconsistent effects on muscle mass, strength, or functional capacity.

If you are an older adult doing resistance training, adding protein or amino acid supplements will likely help you gain a small amount of lean body mass (roughly 0.2-0.8 kg more than exercise alone). However, do not expect significant increases in strength, muscle size, or physical function from the supplement alone; the exercise is doing the heavy lifting. This benefit is most noticeable in frail or sarcopenic individuals, whereas those who are obese may see little to no benefit.

Nutritional interventions (protein, leucine, HMB, creatine) preserve or modestly increase lean mass in sarcopenia but fail to consistently restore muscle strength or physical function when applied in isolation.

Eat enough protein (at least 1.2g per kg of body weight daily) and consider creatine or HMB, but do not expect these supplements to fix your strength or balance on their own. You must combine them with resistance exercise to see functional benefits. Nutrition primes the muscle, but exercise builds the function.

During COVID-19 stay-at-home mandates, older adults with type 2 diabetes experienced significant weight loss (average 2.1%) rather than the weight gain often reported in younger populations.

If you are an older adult with type 2 diabetes, do not assume the pandemic shutdown will automatically cause weight gain. This study found that the majority of participants actually lost weight. However, those who did gain weight reported more negative impacts on their health and access to food, so monitoring your weight and mental well-being is still important.

Among older adults with type 2 diabetes, those who gained weight during the pandemic reported significantly more negative psychosocial and behavioral impacts than those who lost weight.

If you gained weight during the pandemic, you are not alone, but you may be experiencing more stress, sleep issues, or access problems than those who lost weight. Focus on addressing these specific barriers (food access, sleep) rather than just the scale number. If you lost weight, it was likely intentional and not associated with the negative mental health impacts seen in gainers.

Metabolic surgery (VSG/RYGB) alters gut hormone profiles by increasing GLP-1 and PYY while decreasing ghrelin, leading to reduced hunger and improved satiety, which aids in sustained weight loss and glucose control.

Surgery biologically reduces your hunger drive (ghrelin) and increases fullness signals (GLP-1/PYY), making it easier to maintain weight loss compared to dieting alone, which often triggers intense hunger.

Older adults (>30 years) significantly increase their energy intake from ultra-processed foods (UPFs) on weekends compared to weekdays, whereas younger adults (18-30 years) maintain consistent UPF consumption levels regardless of the day of the week.

If you are over 30, your weekend meals are likely driving your high ultra-processed food intake, whereas your weekday habits are stable. To improve your diet, focus your planning efforts specifically on Friday through Sunday. You do not need to change your weekday routine, as your data shows consistency there. Targeting the weekend window is the highest-yield intervention for this demographic.

Younger adults (18-30 years) consume ultra-processed foods (UPFs) in a continuous 'grazing' pattern throughout the day, with distinct peaks at 8 pm and 1 pm, whereas older adults follow conventional three-meal patterns with an additional morning peak.

If you are under 30, you likely snack on ultra-processed foods throughout the day rather than just at meals. Your intake peaks at 1 pm and 8 pm. To reduce UPF intake, focus on eliminating snacks during these specific hours, particularly the late evening peak, rather than just trying to eat 'less' overall.

Resistance, sprint, and power training induce a shift from fast-twitch IIx fibers to the fast-twitch IIa phenotype, with minimal change in pure type I fibers.

If you engage in heavy resistance training, expect your muscle fibers to become more efficient at generating power (shifting from IIx to IIa), but do not worry about losing your slow-twitch endurance fibers. This adaptation supports better performance in power activities without compromising your base endurance.

Endurance training induces a shift toward a more oxidative phenotype, characterized by an increase in Type I fibers and a decrease in Type IIa fibers.

High-volume endurance training will make your muscles more efficient at using oxygen by increasing Type I fibers. If you are an endurance athlete, expect this shift. If you are a strength athlete, be aware that excessive endurance work might reduce your peak power, but you can mitigate this with proper tapering.

Shifting US protein intake by reducing total volume by 25% and changing the animal-to-plant ratio from 85:15 to 60:40 aligns consumption with dietary recommendations while significantly reducing environmental impact.

To improve both your health alignment and environmental impact, reduce your total daily protein intake by about a quarter and shift your sources. Instead of 85% of your protein coming from animal sources (meat, dairy, eggs), aim for 60% animal and 40% plant (beans, lentils, nuts, grains). This shift aligns with official dietary guidelines and significantly lowers your carbon and water footprint without compromising nutritional adequacy for the average adult.

Obesity in Type 1 Diabetes is associated with increased cardiometabolic risk, higher insulin requirements, and an enhanced risk of chronic complications compared to normal-weight T1D patients.

Obesity in T1D is not just about weight; it significantly increases the risk of heart disease, kidney issues, and eye problems due to insulin resistance. Managing weight is critical for long-term complication prevention.

A Low FODMAP diet significantly improves functional gastrointestinal symptoms (pain, bloating, diarrhea) in IBD patients, but does not reduce underlying inflammatory disease activity.

If you have IBD and suffer from bloating, pain, or diarrhea, a Low FODMAP diet can significantly improve these functional symptoms and your quality of life. However, it does not treat the underlying inflammation of IBD, so it should be used alongside standard medical care and ideally under guidance to ensure nutritional adequacy.